All posts byArthritis Foundation

biosimilars substitution victory

Biosimilar Substitution Victories Across the Country!

The Arthritis Foundation thanks the governors in eight states for signingbiosimilar legislationin 2018 that enhances patient access to new and innovative medications, while ensuring that pharmacists are communicating critical, up-to-date medical information about patients to physicians. New laws inConnecticut, Michigan, New Hampshire, South Dakota, Vermont, Wyoming, West Virginia and Wisconsinwill positively impact approximately 5.3 million people with doctor-diagnosed arthritis.

“This legislation will grant access to life-changing medications while ensuring proper safeguards for both patient and physician when a prescription is substituted,” said Connecticut Advocacy Chair Paula Haney.

Continue readingBiosimilar Substitution Victories Across the Country!

take care premium increases

TAKE CARE: Advocacy Blog Series

Premium Increases

We’re excited to continue our advocacy blog series meant to help youtake carewhen it comes to important arthritis health care and coverage issues. If you are just now tuning into this series, check out our previous blog posts onaccumulator adjustment programs, pharmacistgag orders, President Trump’s drug pricingblueprintanddrug rebates.

This week we are focusing on the rise in premiums for health plans sold on the Affordable Care Act exchanges. Read on to learn more about how these increases may or may not impact your health insurance options.Continue readingTAKE CARE: Advocacy Blog Series

drug rebates header

TAKE CARE: Advocacy Blog Series

Drug Rebates

We’re excited to continue our advocacy blog series meant to help youtake carewhen it comes to importantarthritis health care和覆盖问题。如果您现在刚刚进入这个系列,请查看我们以前的博客文章accumulator adjustment programs, pharmacistgag orders, and President Trump’s drug pricingblueprint.

This week we dig in to the world of drug rebates, which are often negotiated between pharmaceutical manufacturers and pharmacy benefit managers (PBMs). Read on to learn more about how drug rebates play a role in the drug supply chain and impact access to medications.

Continue readingTAKE CARE: Advocacy Blog Series

president trump drug pricing blueprint

TAKE CARE: Advocacy Blog Series

President Trump’s Drug Pricing Blueprint

We’re excited to continue our advocacy blog series meant to help youtake carewhen it comes to important arthritis health care and coverage issues. If you are just now tuning into this series, check out our previous blog posts onaccumulator adjustment programsand pharmacistgag orders.

本周,继续阅读,了解更多关于特朗普总统的药品定价蓝图以及该计划涉及的不同政策领域。

Why did the Administration decide to release a drug pricing blueprint?

On Friday, May 11 the Administration released its long-awaited plan, “Putting Patients First,” intended to help lower drug prices and reduce out-of-pocket costs for patients. President Trump has spoken at length about the need to tackle prescription drug prices, and the blueprint released last week was an effort to follow through on that promise.

In response to the blueprint, the Arthritis Foundation released a briefstatementon social media, expressing cautious optimism, but urging thoughtful development of proposals going forward.

Continue readingTAKE CARE: Advocacy Blog Series

arthritis foundation advocacy clawbacks

TAKE CARE: Advocacy Blog Series

Pharmacy Benefit Manager Gag Orders and Clawbacks

We’re excited to present our second blog in a series meant to help youtake carewhen it comes to important arthritis health care and coverage issues. This week we’ll tell you about a practice some pharmacy benefit managers have been using called clawbacks, which affect the price of medications you pay at the pharmacy counter. Read on to learn more and see how the Arthritis Foundation is addressing the issue.

What are clawbacks?

A person who fills his or her prescription at the pharmacy may pay more for a prescription drug with insurance than if he or she had filled it without insurance. This can occur due to a“clawback,”a term used to describe the difference between the cash cost of a drug (purchasing a drug without insurance) and the copayment required by your health plan. That difference, the clawback, is often passed by the pharmacy back to the pharmacy benefit manager (PBM) as a profit. Unfortunately, this often occurs without the patient ever knowing they could avoid the higher copay by paying without insurance. A provision in the contract between the pharmacist and the PBM, known as a“gag order,”prohibits the pharmacist from disclosing cost information related to payment options.

Continue readingTAKE CARE: Advocacy Blog Series

accumulator adjustment programs

TAKE CARE: Advocacy Blog Series

Accumulator Adjustment Programs

We’re excited to present a new advocacy blog series meant to help youtake carewhen it comes to importantarthritis health care和覆盖问题。在接下来的两个月里,我们将每隔一周发布一篇博客,帮助像你这样的病人知道我们正在关注哪些访问问题,以及你能做些什么。本周,我们将告诉你许多药品福利经理(PBMs)正在使用的一项新政策,称为累加调整计划,它可能特别影响那些在高免赔额健康计划中的人。请继续阅读,了解更多关于这些项目的信息,以及它们被实施的原因。Continue readingTAKE CARE: Advocacy Blog Series